Noxopharm White Paper

17 Disclaimer: Veyonda is currently not approved in Australia or any other country Veyonda® – NOXCOVID program NOXCOVID: NOX66 (Veyonda) in COVID-19 Disease A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19 Infection (NOXCOVID) NOXCOVID aims: To demonstrate that in COVID-19 patients at risk of developing cytokine release syndrome ( ‘cytokine storm’ ) and septic shock that: • Veyonda is safe and well tolerated in COVID-19 patients with impaired lung function. • Veyonda can moderate cytokine release syndrome, in particular those cytokines predisposing to coagulopath; and • Veyonda can halt the deterioration of COVID-19 disease and progression to septic shock. NOXCOVID rationale: Idronoxil blocks excessive STING (Stimulator of Interferon Genes) signalling in response to virally- induced lung damage and generalised tissue damage resulting from low pO2 levels. Through this action, it is proposed that Veyonda will moderate the STING response in patients with moderate ARDS (acute respiratory distress syndrome) due to respiratory infections with SARS-CoV-2. NOXCOVID-1 A Phase 1 dose-escalation and dose-expansion study focusing on safety and proof-of-principle endpoints (biomarker and clinical responses). Patient treatment included approximately 40 patients who were admitted to hospital for respiratory insufficiency (not requiring artificial ventilation) associated with the SARS-CoV-2 virus. The aim is to prevent the onset of a cytokine storm that inflicts tissue damage in the lungs and other major organs, aggravating lung damage and requiring mechanical ventilation and potentially causing death. Veyonda is not intended to replace other potential treatments, like dexamethasone that may provide a clinical benefit in patients with more advanced disease already experiencing a cytokine storm.